Thymectomy, the surgical removal of the thymus gland, is performed primarily for two reasons: to treat myasthenia gravis (MG), a condition in which the immune system attacks the body’s own nerve-muscle connections, and to remove thymic tumors called thymomas. A landmark randomized trial published in 2016 settled decades of debate by showing that thymectomy genuinely improves outcomes in MG, but a more recent study has raised pointed questions about what losing the thymus costs the body over time. The procedure turns out to sit at a fascinating intersection of surgery, immunology, and oncology, and the tradeoffs are more layered than most patients initially realize.
Why the Thymus Matters More Than People Think
The thymus is a small, two-lobed organ that sits behind the breastbone in the upper chest. Most people associate it with childhood: it is largest in early adolescence and gradually shrinks with age, replaced in part by fatty tissue. That shrinkage led generations of physicians to assume the thymus was largely useless in adults. Research over the last few decades has overturned that assumption. Studies of adults up to their mid-fifties have found that the thymus continues actively producing new immune cells, generating a diverse repertoire of T cells that contribute to the body’s defenses.1PubMed. Generation of functional thymocytes in the human adult After events that deplete immune cells, such as chemotherapy or HIV infection, the thymus can even enlarge and ramp up production to help rebuild the immune system.2JCI Insight. Age-dependent incidence, time course, and consequences of thymic renewal in adults
The thymus also plays a critical role in self-tolerance, the process by which the immune system learns not to attack the body’s own tissues. A gene called AIRE drives the thymus to display samples of proteins from organs throughout the body, so that developing T cells that would react against those proteins can be eliminated before they ever leave the gland.3PubMed Central. AIRE in the thymus and beyond When that process goes wrong, autoimmune disease can follow. This dual role of the thymus, producing new immune soldiers while simultaneously screening out rogue ones, is what makes its removal both medically useful in certain diseases and immunologically consequential.
Thymectomy for Myasthenia Gravis
For most of the twentieth century, surgeons removed the thymus in MG patients based on clinical experience, but without rigorous proof that it worked better than medication alone. That changed with an international randomized trial that compared thymectomy plus the steroid prednisone against prednisone alone in patients with MG who did not have thymomas. Over three years, patients who had thymectomy had meaningfully lower disease severity scores and needed substantially less prednisone, averaging about 44 mg on alternate days compared with 60 mg in the medication-only group.4PubMed. Randomized Trial of Thymectomy in Myasthenia Gravis The benefits held up and actually widened at five years: the thymectomy group averaged roughly half the prednisone dose of the control group, and their disease scores remained significantly better.5The Lancet Neurology. Long-term outcomes of thymectomy for non-thymomatous myasthenia gravis (MGTX): an extension study
Those results matter for day-to-day quality of life. Prednisone is effective for MG, but long-term use causes weight gain, bone loss, diabetes, and mood changes. Being able to cut the dose in half makes a real difference. Quality-of-life studies after thymectomy for MG have found that patients eventually recover normal physical function and working ability, though some lingering emotional and energy-related effects can persist.6PubMed Central. Long-term outcome and quality of life after thymectomy for myasthenia gravis
Not All MG Patients Respond Equally
The type of antibody driving a patient’s MG affects how much they stand to gain from thymectomy. Patients with the most common form, driven by antibodies against the acetylcholine receptor, had the best outcomes: roughly half achieved stable complete remission within five years of surgery. Patients who tested negative for those antibodies fared somewhat worse, and those with antibodies against a different target called MuSK had the lowest remission rates, around 20% at five years.7PubMed. A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis This is why neurologists now factor antibody status into the decision. For MuSK-positive MG in particular, thymectomy is generally considered less effective, and many specialists avoid recommending it.
Thymectomy for Thymomas
When the thymus itself develops a tumor, surgery is the primary treatment regardless of whether the patient also has MG. Thymomas are uncommon but not vanishingly rare, and they behave unpredictably. Even tumors that appear well-contained under the microscope can recur years or decades later. In a large series of over 300 patients who had complete thymoma removal, five-year overall survival was around 91%, but the ten-year rate dropped to about 74%, with roughly one in six patients experiencing recurrence.8PubMed Central. Long-term outcomes of 307 patients after complete thymoma resection Another series reported five-year survival of 95% and fifteen-year survival of 91%, though recurrences still appeared across the follow-up period, most commonly as pleural deposits rather than local regrowth in the chest.9Journal of Thoracic Oncology. Long-Term Outcomes and Risk Factors for Recurrence after Resection of Thymic Epithelial Tumors
The stage at diagnosis and the tumor’s microscopic type are the strongest predictors of how things go. More advanced stages and more aggressive cell types carry higher recurrence risk. Because even apparently cured thymomas can come back after many years, a case report documented recurrence a full 32 years after seemingly complete removal of a low-stage tumor.10The Annals of Thoracic Surgery. Recurrence of stage I thymoma 32 years after total excision Lifelong surveillance with periodic chest imaging is standard practice.
Open Surgery Versus Minimally Invasive Approaches
The traditional approach to thymectomy involves splitting the breastbone down the middle, a procedure called median sternotomy. It gives the surgeon excellent visibility but requires a large incision, involves considerable postoperative pain, and means a longer hospital stay. Over the past two decades, minimally invasive techniques, both camera-assisted (VATS) and robotic, have become increasingly common. A systematic review comparing robotic thymectomy to the open approach found that robotic surgery resulted in substantially less blood loss, fewer complications, shorter hospital stays, and a lower rate of positive surgical margins, with no difference in operating time.11PubMed Central. A systematic review of robotic versus open and video assisted thoracoscopic surgery (VATS) approaches for thymectomy
A national analysis comparing open and minimally invasive thymectomy for thymomas across stages I through III found that the minimally invasive group had a shorter hospital stay, with no significant differences in margin status, readmission rates, short-term mortality, or five-year survival.12PubMed. A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma A propensity-matched comparison of robotic and open sternotomy for early-stage thymoma confirmed the pattern: robotic patients had less blood loss, fewer complications, and shorter hospital stays, with the open group actually costing more overall because of the longer hospitalization.13European Journal of Cardio-Thoracic Surgery. Comparing robotic and trans-sternal thymectomy for early-stage thymoma: a propensity score-matching study
Tumor size matters when choosing the surgical route. For tumors up to about four centimeters, robotic surgery was associated with better odds of achieving a clean margin than open surgery. For tumors between four and eight centimeters, the approaches performed similarly. For the largest tumors, there was no clear advantage either way, and survival at five and ten years was comparable regardless of how the operation was done.14PubMed Central. Margin-negative resection and long-term survival following robot-assisted thymectomy for thymoma: A tumor size stratified analysis
The Problem of Ectopic Thymic Tissue
One underappreciated surgical challenge is that thymic tissue does not always stay neatly within the gland itself. Fat deposits scattered throughout the chest can harbor pockets of functional thymus. A study examining patients without any thymic disease found thymic tissue in about 71% of them, most commonly in the fat around the pericardium on the left and right sides.15PubMed Central. Distribution of mediastinal ectopic thymic tissue in patients without thymic disease Autopsy studies have found thymic tissue behind the main airway junction and in other areas that would not normally be accessible through a standard sternotomy.16PubMed. Distribution of thymic tissue in the mediastinal adipose tissue Earlier histological work similarly showed that the surrounding fat often contains thymic tissue, including the characteristic cellular structures that prove it is functionally active.17PubMed. Distribution of thymic tissue at the anterior mediastinum. Current procedures in thymectomy
This matters for two reasons. In MG patients, leftover thymic tissue may continue producing the rogue immune cells that drive the disease, potentially explaining why some patients do not fully remit after surgery. For thymoma patients, residual tissue could be the origin of a late recurrence. One case report described a thymoma appearing 15 years after an extended thymectomy, likely arising from tissue near the phrenic nerve that had been deliberately left behind to avoid nerve damage.18European Journal of Cardio-Thoracic Surgery. Appearance of thymoma 15 years after extended thymectomy for myasthenia gravis without thymoma This is why many surgeons now advocate for “maximal” or “extended” thymectomy, removing not just the gland but as much surrounding mediastinal fat as possible.
The Perioperative Window for MG Patients
The most feared short-term complication for MG patients undergoing thymectomy is postoperative myasthenic crisis, a severe worsening of muscle weakness that can compromise breathing. In one series, about 10% of MG patients with thymomas developed crisis after surgery, with those affected needing a median of nine days on a ventilator and ten days in intensive care.19European Journal of Cardio-Thoracic Surgery. Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis The strongest predictors of crisis include bulbar symptoms before surgery (trouble swallowing, speaking, or breathing), a history of prior crisis, and very high levels of the disease-driving antibodies.20The Journal of Thoracic and Cardiovascular Surgery. Prognostic factors for postoperative myasthenic crisis after transsternal thymectomy in myasthenia gravis Surgeons also need to take particular care to avoid injuring the phrenic nerves, which control the diaphragm. In a patient whose breathing muscles are already compromised by MG, even a minor diaphragm injury can become life-threatening.21PubMed Central. Summary of the best evidence for the prevention and management of myasthenic crisis after thymectomy
Long-Term Health Consequences of Losing the Thymus
A 2023 study in the New England Journal of Medicine sent a jolt through the surgical community. Researchers tracked adults who had undergone thymectomy during cardiothoracic surgery (mostly for reasons other than MG) and compared them to matched patients who had similar operations but kept their thymus. Five years after surgery, the thymectomy group had roughly triple the rate of death from any cause compared to controls, and about double the rate of cancer.22PubMed Central. Health Consequences of Thymus Removal in Adults Compared to the general U.S. population, the thymectomy group’s all-cause mortality and cancer-related mortality were both elevated. The findings prompted a multidisciplinary review of the evidence, examining whether these risks apply equally to all people who lose their thymus.23PubMed Central. Does Surgical Removal of the Thymus Have Deleterious Consequences?
The critical nuance is that MG patients who undergo thymectomy may not face the same elevated risks. A study comparing several groups found that no deaths and no post-thymectomy cancers occurred in the MG-thymectomy group, while the non-MG thymectomy group had a death rate of about 14% and developed 18 new cancers. Meanwhile, MG patients who did not have thymectomy had the highest mortality rate in the study.24PubMed Central. Survival and autoimmune risks post-thymectomy One possible explanation is that the dysfunctional thymus in MG patients is already causing harm, and removing it trades a real, ongoing disease burden for a theoretical long-term immune cost. By contrast, removing a healthy thymus from someone who doesn’t need the operation may carry only downside. The science on this distinction is still young, but it already suggests that the 2023 findings should not be used as a blanket argument against thymectomy for MG or thymoma.
What Happens to the Immune System After Early-Life Thymectomy
Thousands of children each year have their thymus partially or completely removed during corrective heart surgery, because the gland sits directly in the surgical field and must be moved or excised for access to the heart. The immune consequences have been studied extensively. Children thymectomized as newborns show persistent drops in total lymphocyte counts, especially naive T cells, the freshly minted immune cells that have not yet encountered a pathogen. These changes were evident over three years of follow-up and were accompanied by a rise in the signaling molecule IL-7, which the body produces when it senses a T-cell shortage.25Clinical and Experimental Immunology. Longitudinal analysis of immune function in the first 3 years of life in thymectomized neonates during cardiac surgery
Longer-term studies paint a more detailed picture. In one follow-up of patients who had heart surgery as infants, about a quarter had low lymphocyte counts years later, with their immune profile shifted toward a pattern that resembles premature aging of the immune system. Reassuringly, vaccine responses remained positive in about 90% of them, suggesting that everyday immune function holds up reasonably well despite the measurable changes.26PubMed. Long-term immunological changes after corrective cardiac surgery An 18-year follow-up of people thymectomized before six months of age found that the diversity of their T-cell receptor repertoire, basically the breadth of threats their immune system can recognize, was reduced in both major T-cell types.27Journal of Allergy and Clinical Immunology. T-cell receptor sequencing reveals decreased diversity 18 years after early thymectomy A more recent study using advanced sequencing confirmed the same pattern and additionally found an increase in a particular type of immune cell that may reflect the body’s attempt to compensate for the loss of conventional T cells.28Nature Communications. Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease
The practical question parents and cardiologists ask is whether these lab abnormalities translate into real-world health problems. So far, the children studied have not experienced more infections than their peers, and most respond well to vaccines. But the concern is that a narrowed immune repertoire could become a vulnerability later in life, particularly if these individuals face a severe infection, need chemotherapy, or develop an immune-depleting condition and require their immune system to rebuild from scratch. That rebuilding would normally depend heavily on the thymus.
Imaging Before Surgery
Distinguishing a thymic tumor from simple thymic enlargement (hyperplasia) matters enormously because the treatment is different. CT scans are the standard first step, but MRI can be valuable in ambiguous cases. Chemical-shift MRI sequences can distinguish fat-containing hyperplastic thymus from a solid thymoma, which helps avoid unnecessary surgery. Diffusion-weighted MRI can separate normal or hyperplastic thymus from tumor tissue and may even help gauge tumor aggressiveness. PET-CT scans, which detect metabolic activity, are less useful for telling early-stage thymomas apart from advanced ones but can help differentiate the rarer and more dangerous thymic carcinoma from ordinary thymoma.29PubMed. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor
Thymus Transplantation and Regenerative Approaches
While thymectomy removes the organ, a small but growing field is working on the opposite problem: giving a functioning thymus to people who were born without one. Congenital athymia is a rare condition in which the thymus never develops, leaving children profoundly immunodeficient. An FDA-approved treatment uses cultured donor thymus tissue, implanted surgically, to reconstitute the patient’s immune system. The implanted tissue attracts the recipient’s own immune precursor cells, which then mature into functional T cells.30PubMed. Cultured thymus tissue implantation for congenital athymia: Surgical site complications and dose-effect analysis Research into cryopreserved thymic tissue transplantation has shown that even frozen-then-thawed tissue can colonize a recipient and generate new naive T cells that are tolerant to the donor, which has implications not just for athymia but potentially for transplant tolerance more broadly.31PubMed Central. Reconstitution of thymopoiesis via implantation of cryopreserved cultured thymus tissue into athymic recipients
These advances raise an intriguing possibility for the future: could thymus transplantation eventually offset the immune costs of thymectomy in adults who need the operation? That remains speculative, but the proof-of-concept work is already in clinical use for children, which is more than most regenerative therapies can claim.
Eighty Years of Controversy
The history of thymectomy for myasthenia gravis is unusually contentious for a surgical procedure. Alfred Blalock performed the first one in 1936, and by the 1950s a transatlantic argument had erupted between the British surgeon Geoffrey Keynes, who championed the operation, and American neurologists and surgeons who remained skeptical. The debate dragged on for decades, with increasingly sophisticated statistical analyses applied to retrospective data, none of which could settle the question definitively. The consensus that eventually formed was challenged again in the late 1970s, ultimately prompting the randomized trial that would not report results until 2016, eighty years after the first operation.32PubMed Central. Surgical innovation, statistical analysis, and professional culture: thymectomy for myasthenia gravis, 1936-2016 The story is a useful reminder that in surgery, where it is difficult to run blinded trials, even effective procedures can remain genuinely controversial for generations.